Accurate Education - Melatonin for Chronic Pain: A Patient Guide

Nutraceuticals:

Melatonin for Chronic Pain: A Patient Guide

Melatonin shows promise as a supplemental therapy for chronic pain, particularly in conditions like fibromyalgia, endometriosis, and irritable bowel syndrome, by improving sleep quality and acting as an analgesic via anti-inflammatory mechanisms. It is considered safe and well-tolerated, with potential to reduce reliance on higher-risk medications.

See:

Melatonin

Nutraceutical Patient Guides:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Melatonin for Chronic Pain: A Patient Guide

1. INTRODUCTORY OVERVIEW

Melatonin shows promise as an adjuvant therapy for chronic pain, particularly in conditions like fibromyalgia, endometriosis, and irritable bowel syndrome, by improving sleep quality and acting as an analgesic via anti-inflammatory mechanisms. It is considered safe and well-tolerated, with potential to reduce reliance on higher-risk medications.

Melatonin is a hormone naturally produced by your pineal gland, primarily at night, that regulates your sleep-wake cycle (circadian rhythm). Beyond its well-known role in sleep, melatonin has emerged as a potential therapeutic agent for chronic pain due to its anti-inflammatory, antioxidant, and direct analgesic properties.

What makes melatonin valuable for chronic pain:

Activates MT1 and MT2 melatonin receptors in pain-processing areas of the brain and spinal cord
Reduces pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) throughout the body
Provides potent antioxidant protection, particularly in mitochondria
Modulates the opioid and GABAergic systems to reduce pain signaling
Improves sleep quality, which indirectly reduces pain perception
Has an excellent safety profile with minimal side effects

How melatonin compares to conventional medications:

A 2020 meta-analysis of 30 randomized, double-blind, placebo-controlled trials (1,967 participants) found that melatonin significantly reduced chronic pain. For migraine prevention, a 2026 meta-analysis of 9 RCTs (788 patients) found melatonin reduced headache days, severity, and analgesic use compared to placebo, with a response rate 38% higher than placebo. Melatonin 3 mg was found to be as effective as amitriptyline 25 mg for migraine prevention but with significantly better tolerability.

Unlike many conventional pain medications, melatonin does not cause dependence, tolerance, or significant cognitive impairment. However, recent evidence is mixed—a 2025 RCT found no benefit for neuropathic pain specifically, suggesting melatonin may work better for certain pain conditions than others.

—

2. DIETARY SOURCES

Melatonin is found naturally in various foods:

Tart cherries/cherry juice: One of the richest sources; shown to increase urinary melatonin metabolites
Eggs: Good animal source of melatonin
Fish: Contains measurable amounts
Nuts (especially pistachios, walnuts): High plant sources
Grapes and wine: Contain melatonin
Tomatoes: Moderate amounts
Peppers: Contain melatonin
Mushrooms: Variable amounts
Cereals (rice, barley, oats): Contain melatonin
Milk (especially night-time milked cows): Contains melatonin

Tryptophan-rich foods (precursor to melatonin): soybeans, pumpkin seeds, sesame seeds, turkey, chicken, eggs, cheese, fish

Important Bioavailability Note: Dietary sources provide only small amounts of melatonin compared to therapeutic doses. Oral melatonin supplements have variable bioavailability (approximately 9-33%, with an average of ~15%) due to significant first-pass metabolism in the liver.[1]

Immediate-release formulations produce a rapid peak and decline, while sustained/extended-release formulations provide more prolonged levels. For pain conditions, immediate-release melatonin 3 mg has the most clinical evidence.

—

3. INDICATIONS FOR NUTRACEUTICAL SUPPLEMENTATION

Pain Conditions with Moderate to High Quality Evidence:

Migraine Prevention – Moderate-High Quality Evidence

A 2026 meta-analysis (9 RCTs, 788 patients) found melatonin reduced attack duration by 5 hours, headache days by 1.5 days/month, and headache severity compared to placebo
Melatonin 3 mg immediate-release was as effective as amitriptyline 25 mg with better tolerability
A 2020 network meta-analysis found melatonin 3 mg had the greatest improvement in migraine frequency among all interventions studied

Fibromyalgia – Moderate Quality Evidence

Melatonin 3-5 mg alone or combined with fluoxetine significantly reduced Fibromyalgia Impact Questionnaire scores
A 2024 pilot study found PEA 1,200 mg + melatonin 0.2 mg improved pain, sleep, and quality of life
Preclinical studies show melatonin protects against fibromyalgia-related muscle damage

Chronic Pain (General) – Moderate Quality Evidence

Meta-analysis of 5 studies showed significant pain reduction (SMD -0.65)
A 2024 RCT found transient improvements in sleep and pain at 3 weeks in severe chronic pain patients

Osteoarthritis – Low-Moderate Quality Evidence

A UK cohort study found melatonin users had 53% lower risk of knee/hip replacement compared to benzodiazepine users
Preclinical evidence shows melatonin protects cartilage and reduces inflammation

Irritable Bowel Syndrome – Low-Moderate Quality Evidence

Clinical studies suggest benefit for IBS-related pain

Neuropathic Pain – Mixed/Inconclusive Evidence

Strong preclinical evidence for efficacy
However, a 2025 RCT (31 patients) found no benefit over placebo

—

4. MELATONIN’S IMPACT ON PAIN CONDITIONS

Melatonin addresses the underlying pathophysiology of chronic pain conditions through multiple mechanisms:

Anti-Inflammatory Actions:

Inhibits NF-κB signaling, reducing production of inflammatory mediators
Reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues
Inhibits cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS)
Suppresses NLRP3 inflammasome activation

Cartilage and Joint Protection (Osteoarthritis):

Promotes cartilage matrix synthesis and inhibits degradation
Activates NRF2/HO-1 antioxidant pathway in chondrocytes
Reduces synovial inflammation and fibrosis
Inhibits ferroptosis (iron-dependent cell death) in cartilage

Muscle Protection (Fibromyalgia):

Reduces inflammatory and oxidative stress markers in skeletal muscle
Improves spontaneous motor activity in preclinical models

—

5. MELATONIN’S IMPACT ON PAIN PROCESSING

Pain processing refers to how pain signals are processed from the initial damaged tissue source of pain through the nerves and spinal cord to the brain and then down the spinal cord again. Melatonin offers potential benefit for reducing the severity of the pain experience by acting at various levels of pain processing.

Level 1: Peripheral Pain Receptor (Nociception Transduction)

MT1 and MT2 receptors are present on sensory neurons
Reduces local inflammatory mediators that sensitize nociceptors
Inhibits 5-lipoxygenase and COX-2, reducing prostaglandin and leukotriene production

Level 2: Primary Afferent Transmission to Spinal Cord

Provides neuroprotection against oxidative damage to peripheral nerves
Reduces neuroinflammation along nerve pathways

Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)

MT2 receptors are localized in the spinal cord dorsal horn
Inhibits NF-κB/NLRP3 inflammasome signaling in spinal cord
Reduces spinal cord cytokine release (TNF-α, IL-1β, IL-18)
Activates SIRT1 pathway, reducing spinal neuroinflammation

Level 4: Ascending Spinal Pathways and Supraspinal Processing

MT2 receptors are present in the reticular and ventromedial nuclei of the thalamus (ascending nociceptive pathway)
Modulates microglial activation in supraspinal structures
Promotes anti-inflammatory M2 microglial phenotype

Level 5: Brain Cortical Processing and Pain Perception

Reduces anxiety, which amplifies pain perception
Improves sleep quality, reducing pain sensitivity
Neuroprotective effects in cortical regions

Level 6: Descending Pain Modulation

MT2 receptors are present in the ventrolateral periaqueductal gray (vlPAG), a key structure in descending pain inhibition
Activates OFF cells and inhibits ON cells in the rostral ventromedial medulla (RVM)
Increases enkephalin precursor gene expression in PAG
Modulates GABAergic and opioidergic descending pathways

—

6. BENEFITS FOR PAIN SENSITIZATION

Peripheral Sensitization: MODERATE Quality Evidence

Reduces peripheral inflammatory mediators (prostaglandins, leukotrienes, cytokines)
Inhibits mast cell activation and degranulation
Provides antioxidant protection to peripheral nerves
Clinical evidence shows dose-dependent increases in pain threshold and tolerance

Central Sensitization: MODERATE Quality Evidence

Inhibits spinal cord NF-κB/NLRP3 inflammasome pathway
Reduces spinal microglial and astrocyte activation
Activates SIRT1 pathway, reducing central neuroinflammation
Modulates descending pain inhibition via vlPAG MT2 receptors
Reduces BDNF levels, which are elevated in central sensitization states

—

7. MELATONIN’S IMPACT ON THE 4 DRIVING FORCES OF CHRONIC PAIN

1. Systemic Inflammation: STRONG EFFECT

A 2021 meta-analysis of 31 clinical trials (1,517 participants) found melatonin significantly reduced:

1. IL-1β
2. IL-6
3. IL-8
4. TNF-α (not significant)

Melatonin inhibits NF-κB activation, reduces COX-2 and iNOS expression, and modulates multiple inflammatory signaling pathways.

2. Neuroinflammation: STRONG EFFECT

Crosses the blood-brain barrier readily
Inhibits microglial activation and promotes M2 (anti-inflammatory) phenotype
Reduces astrocyte activation
Inhibits NLRP3 inflammasome in CNS tissues
Activates AhR/Nrf2/ARE pathway in microglia
Upregulates sirtuins (SIRT1, SIRT3) which have anti-inflammatory effects

3. Oxidative Stress: VERY STRONG EFFECT (Primary Mechanism)

This is one of melatonin’s primary mechanisms of action. Melatonin is synthesized within mitochondria and accumulates there at high concentrations, making it optimally positioned to combat oxidative stress.[2][3] A 2020 meta-analysis of 12 RCTs found melatonin significantly:

1. Increased total antioxidant capacity (TAC)
2. Increased glutathione (GSH) levels
3. Increased superoxide dismutase (SOD) activity
4. Increased glutathione peroxidase (GPx) activity
5. Decreased malondialdehyde (MDA) levels

Melatonin is a potent direct free radical scavenger and also upregulates endogenous antioxidant enzymes.[4]

4. Mitochondrial Dysfunction: VERY STRONG EFFECT

Melatonin is synthesized within mitochondria and accumulates there at high concentrations:[5][2]

Protects the electron transport chain from oxidative damage by reducing electron leakage and preventing bottlenecks caused by reactive nitrogen species[6]
Inhibits mitochondrial permeability transition pore opening
Reduces electron leakage and increases ATP production
Activates SIRT1/PGC-1α pathway, promoting mitochondrial biogenesis
Restores mitochondrial membrane potential in damaged neurons
Promotes mitophagy (removal of damaged mitochondria)
Enhances intramitochondrial antioxidative defense by inducing Mn-SOD and glutathione peroxidase[6]

—

8. DOSING, TIMING, DURATION AND ADMINISTRATION

Recommended Dosing:

Condition	Dose	Timing	Duration
Migraine prevention	3 mg immediate-release	30-60 min before bedtime	Minimum 3 months
Fibromyalgia	3-5 mg	Before bedtime	Minimum 8 weeks
Chronic pain (general)	3-10 mg	Before bedtime	Minimum 4-8 weeks
Sleep-related pain	2-5 mg	30-60 min before bedtime	Ongoing
Osteoarthritis	3-10 mg	Before bedtime	Ongoing

Key Dosing Points:

Most clinical trials for pain used 3 mg immediate-release formulation
Analgesic effects are dose-dependent in experimental studies
Higher doses (up to 10-12 mg) have been used safely in some trials
A phase II trial found significant analgesic effects at 0.15-0.25 mg/kg (approximately 10-17 mg for a 70 kg adult)

Timing:

Take 30-60 minutes before desired sleep time
Consistent timing is important for circadian rhythm effects
Taking melatonin at the wrong time can disrupt circadian rhythms

Duration of Onset:

Sleep effects: Often within 1-2 weeks
Pain effects: May require 4-8 weeks for meaningful improvement
Migraine prevention: Typically assessed at 3 months

—

9. FORMULATION CONSIDERATIONS

Immediate-Release vs. Extended-Release:

Immediate-release (IR): Produces rapid peak; most clinical evidence for pain is with IR 3 mg
Extended-release/Sustained-release: Provides more prolonged levels; may be better for sleep maintenance. A comparative study found sustained-release melatonin had a 5-fold longer half-life (5.10 h vs 1.01 h) compared to immediate-release[7]
Circadin™ (2 mg prolonged-release): Licensed in some countries; showed transient benefits in chronic pain
Soft gel capsules: May improve bioavailability compared to powder formulations[8]

Quality Considerations:

Melatonin is a dietary supplement in the US and not subject to FDA drug standards
Choose USP (United States Pharmacopeial Convention) Verified products for reliability
Studies have found significant variability in actual melatonin content vs. labeled dose in supplements
Pharmaceutical-grade melatonin (prescription in some countries) offers more consistent quality

—

10. SYNERGIES WITH OTHER PAIN MEDICATIONS AND NUTRACEUTICALS

Nutraceuticals:

Palmitoylethanolamide (PEA): A 2024 pilot study found PEA 1,200 mg + melatonin 0.2 mg significantly improved pain, sleep, and quality of life in fibromyalgia
Tryptophan: Precursor to melatonin; may enhance melatonin synthesis
Vitamin B6: Cofactor in melatonin synthesis pathway
Magnesium: May enhance melatonin’s sleep effects

Conventional Medications:

Opioids (morphine, tramadol): Melatonin enhances opioid analgesia and may reduce opioid tolerance development. Co-administration reduces morphine requirements and attenuates morphine-induced hyperalgesia. Melatonin alleviates morphine tolerance by decreasing NLRP3 inflammasome activation and inhibiting microglial activation[9][10][11]
Fluoxetine: Melatonin 3-5 mg combined with fluoxetine 20 mg showed superior efficacy in fibromyalgia compared to either alone
Amitriptyline: Melatonin 3 mg was as effective as amitriptyline 25 mg for migraine prevention with better tolerability
Gabapentinoids: Theoretical synergy through complementary mechanisms; no direct interaction studies

—

11. DRUG INTERACTIONS

Clinically Significant Interactions:

Warfarin: Case reports of altered INR; monitor closely if combining
Antihypertensives: Melatonin may affect blood pressure; monitor
Immunosuppressants: Melatonin has immunomodulatory effects; use with caution
Diabetes medications: Melatonin may affect glucose tolerance; monitor blood sugar
Sedatives/CNS depressants: Additive sedation possible
Fluvoxamine: Inhibits melatonin metabolism (CYP1A2); may increase melatonin levels significantly

Theoretical Considerations:

Melatonin is metabolized primarily by CYP1A2 in the liver
CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, cimetidine) may increase melatonin levels
CYP1A2 inducers (smoking, carbamazepine) may decrease melatonin levels
Pharmacokinetics is affected by age, caffeine, smoking, oral contraceptives, feeding status, and fluvoxamine[1]

Generally Safe Combinations:

NSAIDs
Acetaminophen
Most antidepressants (except fluvoxamine)
Gabapentinoids

—

12. SAFETY AND CONTRAINDICATIONS

Generally Favorable Safety Profile:

Multiple systematic reviews confirm melatonin is well-tolerated with few serious adverse effects.

Common Side Effects (generally mild and transient):

Daytime drowsiness/fatigue (1.66%)
Headache (0.74%)
Dizziness (0.74%)
Nausea
Vivid dreams or nightmares

Less Common Side Effects:

Mood changes
Short-term feelings of depression
Hypothermia
Gastrointestinal upset

Contraindications:

Known allergy to melatonin
Autoimmune disorders (melatonin has immunostimulatory effects)
Pregnancy and breastfeeding (insufficient safety data)

Use with Caution:

Epilepsy (case reports of seizure threshold changes)
Depression (may worsen symptoms in some individuals)
Diabetes (may affect glucose tolerance)
Liver disease (melatonin is hepatically metabolized)
Patients taking warfarin or immunosuppressants
Children and adolescents (limited long-term safety data)

—

13. SPECIAL CONSIDERATIONS / TIPS

Timing is critical: Take melatonin at a consistent time, 30-60 minutes before desired sleep
Start low: Begin with 1-3 mg and increase gradually if needed
Immediate-release for pain: Most pain studies used immediate-release 3 mg formulation
Be patient: Allow 4-8 weeks for pain benefits; migraine prevention may take 3 months
Quality matters: Choose USP Verified products from reputable manufacturers
Light exposure: Avoid bright light (especially blue light from screens) after taking melatonin
Circadian alignment: Melatonin works best when taken in alignment with natural circadian rhythms
No tolerance or dependence: Unlike many sleep medications, melatonin does not cause tolerance, dependence, or withdrawal
Opioid-sparing potential: May allow reduction of opioid doses when used in combination[9][12]
Sleep-pain connection: Improving sleep quality may indirectly reduce pain perception
Mixed evidence for neuropathic pain: Recent RCT showed no benefit; may work better for other pain types

—

14. COSTS

Standard melatonin supplements (1-10 mg): $5-15 per month
USP Verified products: $10-20 per month
Extended-release formulations: $15-25 per month
Prescription melatonin (Circadin™, where available): $30-60 per month

Melatonin is one of the most affordable supplements available. It is sold as a dietary supplement in the United States and does not require a prescription. In some countries (UK, EU, Australia), higher doses may require a prescription.

—

Remember: Melatonin works best as part of a comprehensive pain management plan that includes proper medical care, good sleep hygiene, physical activity, stress management, and healthy nutrition.

While melatonin has strong evidence for migraine prevention and moderate evidence for fibromyalgia and general chronic pain, recent evidence suggests it may not be effective for all pain types (particularly neuropathic pain).

Its excellent safety profile makes it a reasonable option to try, especially for patients with pain-related sleep disturbances. Always discuss any new supplement with your healthcare provider before starting.

Key updates: include adding new evidence regarding melatonin’s effects on opioid tolerance (including NLRP3 inflammasome inhibition and microglial modulation), mitochondrial protection mechanisms, and bioavailability data.

References

Clinical Pharmacokinetics of Melatonin: A Systematic Review. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. European Journal of Clinical Pharmacology. 2015;71(8):901-9. doi:10.1007/s00228-015-1873-4.
Melatonin: A Mitochondrial Resident With a Diverse Skill Set. Reiter RJ, Sharma R, Rosales-Corral S, de Campos Zuccari DAP, de Almeida Chuffa LG. Life Sciences. 2022;301:120612. doi:10.1016/j.lfs.2022.120612.
Protective Effects of Melatonin and Mitochondria-Targeted Antioxidants Against Oxidative Stress: A Review. Ramis MR, Esteban S, Miralles A, Tan DX, Reiter RJ. Current Medicinal Chemistry. 2015;22(22):2690-711. doi:10.2174/0929867322666150619104143.
Melatonin as an Antioxidant: Under Promises but Over Delivers. Reiter RJ, Mayo JC, Tan DX, et al. Journal of Pineal Research. 2016;61(3):253-78. doi:10.1111/jpi.12360.
Dysfunctional Mitochondria in Age-Related Neurodegeneration: Utility of Melatonin as an Antioxidant Treatment. Reiter RJ, Sharma RN, Manucha W, et al. Ageing Research Reviews. 2024;101:102480. doi:10.1016/j.arr.2024.102480.
Melatonin and the Electron Transport Chain. Hardeland R. Cellular and Molecular Life Sciences : CMLS. 2017;74(21):3883-3896. doi:10.1007/s00018-017-2615-9.
Comparative Pharmacokinetics of Sustained-Release Versus Immediate-Release Melatonin Capsules in Fasting Healthy Adults: A Randomized, Open-Label, Cross-Over Study. Thanawala S, Abiraamasundari R, Shah R. Pharmaceutics. 2024;16(10):1248. doi:10.3390/pharmaceutics16101248.
Soft Gel Capsules Improve Melatonin’s Bioavailability in Humans. Proietti S, Carlomagno G, Dinicola S, Bizzarri M. Expert Opinion on Drug Metabolism & Toxicology. 2014;10(9):1193-8. doi:10.1517/17425255.2014.943183.
Melatonin and Morphine: Potential Beneficial Effects of Co-Use. Hemati K, Pourhanifeh MH, Dehdashtian E, et al. Fundamental & Clinical Pharmacology. 2021;35(1):25-39. doi:10.1111/fcp.12566.
Melatonin Alleviates Morphine Analgesic Tolerance in Mice by Decreasing NLRP3 Inflammasome Activation. Liu Q, Su LY, Sun C, et al. Redox Biology. 2020;34:101560. doi:10.1016/j.redox.2020.101560.
Melatonin Reverses Morphine Tolerance by Inhibiting Microglia Activation and HSP27 Expression. Lin SH, Huang YN, Kao JH, et al. Life Sciences. 2016;152:38-43. doi:10.1016/j.lfs.2016.03.032.
Molecular Mechanism of Neuroprotective Effect of Melatonin on Morphine Addiction and Analgesic Tolerance: An Update. Su LY, Liu Q, Jiao L, Yao YG. Molecular Neurobiology. 2021;58(9):4628-4638. doi:10.1007/s12035-021-02448-0.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.